

# A Systematic Review and Meta-Analysis on the Strength and Consistency of the Associations between Dupuytren Disease and Diabetes Mellitus, Liver Disease, and Epilepsy

Dieuwke C. Broekstra, Ph.D.  
Henk Groen, M.D., Ph.D.  
Sanne Molenkamp, M.D.  
Paul M. N. Werker, M.D.,  
Ph.D.  
Edwin R. van den Heuvel,  
Ph.D.

Groningen and Eindhoven,  
The Netherlands



**Background:** The role of diabetes mellitus, liver disease, and epilepsy as risk factors for Dupuytren disease remains unclear. In this systematic review and meta-analysis, the strength and consistency of these associations were examined.

**Methods:** The MEDLINE, EMBASE, and Web of Science databases were searched for articles reporting an association between Dupuytren disease and diabetes mellitus, liver disease, and epilepsy published before September 26, 2016. The frequencies of Dupuytren disease and diabetes mellitus, liver disease, and epilepsy were extracted, as was information on potential confounders. Generalized linear mixed models were applied to estimate pooled odds ratios, adjusted for confounders. Heterogeneity between studies was quantified using an intraclass correlation coefficient and was accounted for by a random effect for study.

**Results:** One thousand two hundred sixty unique studies were identified, of which 32 were used in the meta-analyses. An association between Dupuytren disease and diabetes mellitus was observed (OR, 3.06; 95 percent CI, 2.69 to 3.48, adjusted for age), which was stronger for type 1 diabetes mellitus than for type 2 diabetes mellitus but was not statistically significant ( $p = 0.24$ ). An association between Dupuytren disease and liver disease was observed (OR, 2.92; 95 percent CI, 2.08 to 4.12, adjusted for sex). Dupuytren disease and epilepsy were associated, yielding an OR of 2.80 (95 percent CI, 2.49 to 3.15). Heterogeneity between studies was moderate to low.

**Conclusions:** These findings demonstrate an association between Dupuytren disease and diabetes mellitus, liver disease, and epilepsy. Prospective, longitudinal studies are needed to elucidate the pathways causing these associations. (*Plast. Reconstr. Surg.* 141: 367e, 2018.)

The precise cause of Dupuytren disease remains incompletely understood. Genetic factors are clearly involved in the pathogenesis of

Dupuytren disease, as illustrated by family studies and by a genomewide association study.<sup>1-3</sup> In addition, environmental factors are believed to play a role in the development of the condition. Dupuytren disease has been observed in association with hand trauma, manual work, smoking, and excessive alcohol consumption.<sup>4-7</sup> Moreover, Dupuytren

From the Departments of Plastic Surgery and Epidemiology, University of Groningen, University Medical Center Groningen; and the Department of Mathematics and Computer Science, Eindhoven University of Technology.

Received for publication February 28, 2017; accepted September 21, 2017.

Presented at the International Symposium on Dupuytren Disease, in Groningen, The Netherlands, May 22 through 23, 2015.

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/PRS.0000000000004120

**Disclosure:** The authors have no financial interest to declare in relation to the content of this article.

Supplemental digital content is available for this article. Direct URL citations appear in the text; simply type the URL address into any Web browser to access this content. Clickable links to the material are provided in the HTML text of this article on the Journal's website (www.PRSJournal.com).

disease has often been linked to diseases such as diabetes mellitus, liver disease, and epilepsy.<sup>4,8-12</sup>

In particular, diabetes mellitus has frequently been studied in relation to Dupuytren disease, and diabetes mellitus is considered an important risk factor for the development of Dupuytren disease.<sup>9,13,14</sup> However, the studies reporting an association between Dupuytren disease and diabetes mellitus have conflicting results. In some studies, a strong association between the two conditions was observed,<sup>15-17</sup> but these results could not always be replicated in other studies.<sup>18,19</sup>

Liver disease has also frequently been associated with Dupuytren disease, although it is thought that excessive alcohol consumption might be responsible for this association. Therefore, it might be worthwhile to elucidate the role of alcohol consumption in this relation. The association between Dupuytren disease and epilepsy has frequently been the subject of study in older articles.<sup>20-24</sup> Again, some studies reported this association and others did not. This discrepancy may be caused by the fact that Dupuytren disease is thought to be associated with specific anticonvulsant drugs, mainly barbiturates, that are not often prescribed anymore. This might explain why some recent studies did not demonstrate an association between Dupuytren disease and epilepsy.<sup>6,8</sup>

In summary, the precise relationship between Dupuytren disease and diabetes mellitus, liver disease, and epilepsy remains unclear. The discrepancy in study results may be caused by heterogeneity between study populations. Also, the lack of controlling for age or sex as confounding factors might lead to an incorrect estimation of the association. In addition, some small studies may individually be underpowered to show an association. Until now, no systematic review or meta-analysis has been conducted to estimate the strength of the association between Dupuytren disease and diabetes mellitus, liver disease, and epilepsy. Therefore, the aim of the current study was to examine the strength and consistency of these associations in published studies reporting an association between Dupuytren disease and diabetes mellitus, liver disease, and epilepsy, to end the ongoing debate about the role of diabetes mellitus, liver disease, and epilepsy as potential risk factors for Dupuytren disease.

## PATIENTS AND METHODS

### Literature Search and Article Assessment

A literature search was conducted on July 11, 2013, using the MEDLINE, EMBASE, and Web of Science databases, using the queries reported in

Table 1. These queries were formulated in cooperation with an information specialist of our medical library. No restrictions on language or publication date were imposed. On September 16, 2016, the searches were updated.

Subsequently, two independent observers assessed the articles in three rounds, following the predefined inclusion and exclusion criteria as presented in Table 2. Although each article was assessed by only two observers, there were three observers in total [D.C.B., A.A.J.B. (see Acknowledgement), and S.M.]. Observer D.C.B. assessed all articles. Because of circumstances, the activities of observer A.A.J.B. were discontinued and carried on by observer S.M. In the first round, the titles and abstracts were assessed. If no abstract was available, the keywords and Medical Subject Headings terms were assessed. In case the keywords or Medical Subject Headings terms contained Dupuytren disease (or Dupuytren contracture, or fibromatosis) in combination with diabetes mellitus, liver disease, or epilepsy, the full text was screened. In all rounds, inconsistencies were discussed to come to consensus. If consensus could not be reached, a third observer (P.M.N.W.) was consulted. Articles were included if they provided sufficient data to calculate either the prevalence of Dupuytren disease in diabetes mellitus, liver disease, or epilepsy, or allowed the calculation of an odds ratio of these associations.

To correct for the confounding effect of age on the association between Dupuytren disease and diabetes mellitus, articles were included only if the age for both case and control groups was reported, or if the participants were matched on age. Sex is likely to be a confounder for the association between Dupuytren disease and liver disease; thus, we excluded the articles that did not report the sex in both case and control groups, or that did not match on sex. Because we could not identify potential confounders for the association between Dupuytren disease and epilepsy, there were no further exclusion criteria for this research question.

### Data Extraction and Statistical Analyses

The primary outcome was the frequency of Dupuytren disease in the diabetes mellitus, liver disease, epilepsy, and control groups. The data were entered in a database by two observers independently. Articles that were published by the same authors having comparable titles were checked for data overlap. If the data overlap was larger than 50 percent, only the study reporting the most complete data was included

**Table 1. Search Strategies Used for the Different Databases**

| Database       | Search Query   |
|----------------|--|
| MEDLINE        | ("Dupuytren Contracture"[Mesh] OR dupuytren*[TIAB]) AND (Epidemiol*[TIAB] OR "epidemiology" [Subheading] OR "etiology" [Subheading] OR associat*[TI] OR "Causality"[Mesh] OR "Epidemiologic Measurements"[Mesh])                             |
| EMBASE         | dupuytren*:ab,ti AND ('epidemiology':ab,ti OR 'epidemiology'/exp OR 'epidemiological data'/exp OR 'etiology'/de OR 'disease association'/exp OR associat*:ti OR 'risk factor'/exp OR 'risk factor':ab,ti) NOT [medline]/lim AND [embase]/lim |
| Web of Science | TS=((dupuytren* AND (etiolo* OR epidemiol*))) AND TI=((Dupuytren* OR fibromatos*)) AND TI=((etiolo* OR epidemiol* OR associat*))   |

**Table 2. Predefined Inclusion and Exclusion Criteria Used in the Different Rounds**

|                     |  |
|---------------------|--|
| Title and abstract  |  |
| Inclusion criterion | Dupuytren disease as subject of research   |
| Exclusion criteria  | No original data/review<br>Not about association of DD and DM, liver disease, or epilepsy  |
| Full-text analysis  |  |
| Inclusion criterion | Articles in Dutch, German, French, or English language   |
| Exclusion criteria  | Not about association of DD and DM, liver disease, or epilepsy<br>No control group<br>No physical examination performed to diagnose DD<br>Case reports<br>Conference abstract<br>No original data<br>Data overlap (>50%) |
| Data extraction     |  |
| Exclusion criteria  | No data reported on age or sex, nor matched for age or sex<br>Incomplete data reported   |

DD, Dupuytren disease; DM, diabetes mellitus.

in the analyses. During the data extraction, the prevalence of Dupuytren disease was expressed in percentages of participants, and articles were excluded in case the prevalence was reported as percentages of hands.

Data were described by presenting the prevalence of Dupuytren disease, and ranges and forest plots are provided to show the odds ratios among studies. A generalized linear mixed model was used to estimate a pooled odds ratio using the procedure NLMIXED of SAS version 9.4 (SAS Institute, Inc., Cary, N.C.). (See Document, Supplemental Digital Content 1, in which detailed information on the statistical analyses is reported, <http://links.lww.com/PRS/C637>.) The statistical analysis method used a generalized mixed model on the frequencies, with adjustment for potential confounders. Missing data on confounders were imputed.

Heterogeneity was calculated with the intraclass correlation coefficient. The larger the

intraclass correlation coefficient value, the larger the heterogeneity. This value can be interpreted as a measure of consistency. (See Document, Supplemental Digital Content 1, in which detailed information on the statistical analyses is reported, <http://links.lww.com/PRS/C637>.) In all statistical analyses, a significance level of 5 percent was used.

## RESULTS

### Results of the Literature Search

The initial search yielded 1309 articles, of which 1260 were unique (Fig. 1). After assessing the titles and abstracts, 166 articles were subjected to full-text analysis. Some articles reported data on two of the three diseases. These articles were included in all full-text analyses for the two diseases separately. This is the reason why the total number of articles included in the full-text analysis for diabetes mellitus, epilepsy, and liver disease combined, as presented in Figure 1, is larger than 166. In the full-text assessment round, the majority of articles were excluded because there was no control group included in the study. In three articles, a questionnaire was used to diagnose Dupuytren disease instead of a physical examination<sup>7,25,26</sup>; and in one article, the results were presented only for the number of hands, making it impossible to calculate an odds ratio on a participant level.<sup>27</sup> These articles were excluded from the analyses.

Of the 1260 unique articles that were obtained, 39 articles reported data on an association between Dupuytren disease and diabetes mellitus. Although many studies took the possible confounding effect of age into account by matching, in some studies this was lacking.<sup>13,17,28-34</sup> In a large number of articles, age was not reported for subgroups, nor were the participants matched on age.<sup>4,12,15,18,19,35-42</sup> These articles were therefore excluded, along with five articles that reported incomplete data.<sup>27,43-46</sup> A total of 21 articles were included in the meta-analysis on the association between Dupuytren disease and diabetes mellitus




Fig. 1. Flowchart of the study selection process. DD, Dupuytren disease.

(Table 3). They all reported age of the diabetics and control group separately.

With respect to the association between Dupuytren disease and liver disease, nine articles reported data on an association (Table 4). In this association, a potential confounder is sex. The sex distribution was reported in almost all articles.<sup>36,47</sup> Two additional articles were excluded because they reported incomplete data.<sup>39,40</sup> Thus, five articles entered the meta-analysis (Table 4). One of the included articles reported that participants were matched on age and sex, but the sex distribution was not reported. The missing data on sex was imputed for this article.

Seven articles reported data on an association between Dupuytren disease and epilepsy. However, six articles were included in the meta-analysis (Table 5), because one article reported incomplete data.<sup>39</sup> One of the included articles provided data that were separated for the different types of anticonvulsant medication that the participants used.<sup>8</sup>

### Dupuytren Disease and Diabetes Mellitus

The average prevalence of Dupuytren disease was 31 percent (range, 0.45 to 69 percent) in patients with diabetes mellitus (Table 3).<sup>48,49</sup> In controls, the mean average prevalence was 14 percent (range, 0.0 to 49 percent).<sup>16,49</sup> An association between Dupuytren disease and diabetes mellitus (irrespective of the type) was found, indicated by a pooled odds ratio of 3.06 (95 percent CI, 2.69 to 3.48). The heterogeneity between studies was moderate, indicated by an intraclass correlation coefficient of 0.56. This indicates that the consistency was also moderate, which corresponds with the findings with respect to the odds ratios (Fig. 2).

Almost half of the studies specified the type of diabetes mellitus, or reported data for the different types of diabetes mellitus separately.<sup>13,16,28–30,50–53</sup> For type 1 diabetes mellitus, the age-adjusted odds ratio was 3.90 (95 percent CI, 2.48 to 6.12), whereas for type 2 diabetes mellitus an odds ratio of 3.04 (95 percent CI, 2.18 to 4.23) was found. A difference between the odds ratios of type 1 and type 2 diabetes mellitus could not be demonstrated ( $p = 0.24$ ). Heterogeneity was low, as indicated by an intraclass correlation coefficient of 0.05.

### Dupuytren Disease and Liver Disease

The average prevalence of Dupuytren disease was 22.3 percent (range, 18.9 to 47.4 percent) in

patients with liver disease (Table 4).<sup>4,58</sup> In controls, the average prevalence was 9.7 percent (range, 7.5 to 14.0 percent).<sup>58,59</sup> The sex-adjusted odds ratio of the association between Dupuytren disease and liver disease was 2.92 (95 percent CI, 2.08 to 4.12). Heterogeneity was low, as indicated by an intraclass correlation coefficient of 0.05, indicating that the association between Dupuytren disease and liver disease was consistent (Fig. 3). The majority of the studies included participants with liver cirrhosis,<sup>4,57–59</sup> and two articles made a distinction between alcoholic and nonalcoholic liver cirrhosis.<sup>4,59</sup> In one article, the type of liver disease was not reported.<sup>60</sup>

### Dupuytren Disease and Epilepsy

The average prevalence of Dupuytren disease was 40.3 percent (range, 7.9 to 70.5 percent) in patients with epilepsy (Table 5).<sup>49,61</sup> In controls, the average prevalence was 29.2 percent (range, 6.0 to 49.2 percent).<sup>49,61</sup> There was an association between Dupuytren disease and epilepsy (OR, 2.80; 95 percent CI, 2.49 to 3.15). One of these studies provided an odds ratio that was smaller than 1, indicating that epileptic patients were less likely to have Dupuytren disease in this study (Fig. 4). The heterogeneity between studies was moderate, as indicated by an intraclass correlation coefficient of 0.55. Unfortunately, only one study reported frequencies for different medication types,<sup>8</sup> and thus further analyses on medication were not possible.

## DISCUSSION

This meta-analysis showed that Dupuytren disease and diabetes mellitus are strongly associated, even after adjustment for age differences between groups. Furthermore, an association between Dupuytren disease and liver disease adjusted for sex, and between Dupuytren disease and epilepsy was found.

The finding that Dupuytren disease and diabetes mellitus are associated suggests that Dupuytren disease and diabetes mellitus may have common factors that contribute to their pathogenesis. The suspected disease mechanism relates to biochemical changes that occur as a result of diabetes mellitus. It is known that many complications of diabetes mellitus are caused by nonenzymatic glycation of proteins. In the literature, there is increasing evidence for the role of nonenzymatic glycation in fibrotic diseases that are associated with diabetes mellitus, such as cardiomyopathy.<sup>62,63</sup> The biochemical changes

**Table 3. Characteristics of Studies Included in the Analysis on the Association between Dupuytren Disease and Diabetes Mellitus**

| Reference                              | Design*         | Country                | Study Size |          | Study Sample                                       | No. with DD (%) |           | Adjusted for Age          |
|--|-----------------|------------------------|------------|----------|--|-----------------|-----------|---------------------------|
|  |                 |                        | DM         | Controls |  | DM              | Controls  |                           |
|  |                 |                        |            |          |  |                 |           |                           |
| Ardic et al., 2003 <sup>28</sup>       | Case-control    | Turkey                 | 78         | 37       | Patients with DM2 and nondiabetic controls         | 17 (22)         | 1 (3)     | NR                        |
| Aydeniz et al., 2008 <sup>50</sup>     | Case-control    | Turkey                 | 102        | 101      | Patients with DM2 and nondiabetic controls         | 13 (13)         | 4 (4)     | Yes, age-matched controls |
| Bergaoui et al., 1991 <sup>54</sup>    | Case-control    | Tunisia                | 280        | 100      | Patients with DM1 or DM2 and nondiabetic controls  | 79 (28)         | 9 (9)     | Yes, age-matched controls |
| Caghero et al., 2002 <sup>29</sup>     | Case-control    | United States          | 200        | 100      | Patients with DM1 or DM2 and nondiabetic controls  | 32 (16)         | 3 (3)     | NR                        |
| Cederlund et al., 2009 <sup>51</sup>   | Case-control    | Sweden                 | 23         | 35       | Patients with DM2 and nondiabetic controls         | 10 (43)         | 4 (11)    | Yes, age-matched controls |
| Chammas et al., 1995 <sup>52</sup>     | Case-control    | France                 | 120        | 120      | Patients with DM1 or DM2 and nondiabetic controls  | 39 (33)         | 10 (8)    | Yes, age-matched controls |
| Chen et al., 2015 <sup>55</sup>        | Cohort          | Taiwan                 | 606,152    | 609,970  | Patients with DM and nondiabetic controls          | 184 (0)         | 109 (0)   | Yes, age-matched controls |
| Eadington et al., 1991 <sup>30</sup>   | Case-control    | United Kingdom         | 200        | 170      | Patients with DM2 and nondiabetic controls         | 47 (24)         | 31 (18)   | NR                        |
| Geoghegan et al., 2004 <sup>84</sup>   | Case-control    | United Kingdom         | 118        | 2345     | Patients with DM and nondiabetic controls          | 64 (54)         | 757 (32)  | Yes, age-matched controls |
| Gunther and Miosga, 1972 <sup>56</sup> | Case-control    | Germany                | 1000       | 1000     | Patients with DM and nondiabetic controls          | 96 (10)         | 27 (3)    | Yes, age-matched controls |
| Kovacs et al., 2012 <sup>13</sup>      | Case-control    | Romania                | 187        | 197      | Patients with DM1 or DM2 and nondiabetic controls  | 54 (29)         | 29 (15)   | NR                        |
| Macaulay et al., 2012 <sup>64</sup> †  | Case-control    | United States          | 165        | 2647     | Patients with DM and nondiabetic controls          | 114 (69)        | 1292 (49) | Yes, age-matched controls |
| Noble et al., 1984 <sup>44</sup>       | Case-control    | United Kingdom         | 150        | 150      | Patients with DM and nondiabetic controls          | 65 (43)         | 27 (18)   | Yes, age-matched controls |
| Ouedraogo et al., 2009 <sup>48</sup>   | Case-control    | Burkina Faso           | 220        | 440      | Patients with DM1 or DM2, and nondiabetic controls | 1 (0)           | 0 (0)     | Yes, age-matched controls |
| Pal et al., 1987 <sup>31</sup>         | Case-control    | United Kingdom         | 109        | 75       | Patients with DM1 or DM2, and nondiabetic controls | 21 (19)         | 7 (9)     | NR                        |
| Ravid et al., 1977 <sup>17</sup>       | Case-control    | Israel                 | 110        | 1396     | Patients with DM and nondiabetic controls          | 17 (15)         | 9 (1)     | NR                        |
| Renard et al., 1994 <sup>53</sup>      | Case-control    | France                 | 120        | 120      | Patients with DM1 or DM2, and nondiabetic controls | 39 (33)         | 10 (8)    | Yes, age-matched controls |
| Savas et al., 2007 <sup>16</sup>       | Case-control    | Turkey                 | 44         | 60       | Patients with DM2 and nondiabetic controls         | 13 (30)         | 0 (0)     | Yes, age-matched controls |
| Seidler et al., 2001 <sup>32</sup> †   | Case-control    | Germany                | 54         | 582      | Patients with DM and nondiabetic controls          | 32 (59)         | 261 (45)  | NR                        |
| Spring et al., 1970 <sup>33</sup>      | Case-control    | United States          | 400        | 500      | Patients with DM and nondiabetic controls          | 83 (21)         | 27 (5)    | NR                        |
| Zerajic and Finsen, 2004 <sup>34</sup> | Cross-sectional | Bosnia and Herzegovina | 292        | 915      | Patients with DM and nondiabetic controls          | 123 (42)        | 181 (20)  | NR                        |

DD, Dupuytren disease; DM, diabetes mellitus; NR, not reported.

\*Case-control studies were defined as studies including a group of patients suffering from DM, and a control group. Cross-sectional studies were defined as studies including one group, in which the presence of DM and DD was determined.

†In these case-control studies, the presence of DM was determined in a group of Dupuytren patients and in controls.

**Table 4. Characteristics of Articles Included in the Meta-Analysis on the Association between Dupuytren Disease and Liver Disease**

| Study                               | Design*         | Country        | Study Size    |          | Study Sample   | No. with DD (%) |          | What Liver Disease   | Adjusted for Sex     |
|-------------------------------------|-----------------|----------------|---------------|----------|--|-----------------|----------|--|----------------------|
|                                     |                 |                | Liver Disease | Controls |  | Liver Disease   | Controls |  |                      |
| Attali et al., 1987 <sup>4</sup>    | Cross-sectional | France         | 212           | 174      | Patients with alcoholic and nonalcoholic liver disease and nonalcoholic controls, or controls without chronic liver disease                                      | 40 (19)         | 22 (13)  | Alcoholic cirrhosis, noncirrhotic alcoholic liver nonalcoholic chronic liver disease | NR                   |
| Bertrand et al., 1977 <sup>59</sup> | Case-control    | France         | 100           | 100      | Patients with alcoholic and nonalcoholic liver disease and controls from general medical ward without liver disease and without alcohol intoxication as controls | 43 (43)         | 14 (14)  | Alcoholic cirrhosis, nonalcoholic cirrhosis  | Sex-matched controls |
| Davidson et al., 1956 <sup>58</sup> | Case-control    | United States  | 57            | 53       | Patients with liver disease and patients of wards of Boston City Hospital, without liver disease and rarely drinking alcohol as controls                         | 27 (47)         | 4 (8)    | Cirrhosis  | NR                   |
| Noble et al., 1992 <sup>60</sup>    | Case-control    | United Kingdom | 82            | 100      | Patients with liver disease and patients from fracture clinic as controls  | 18 (22)         | 8 (8)    | NR   | Sex-matched controls |
| Su and Patek, 1970 <sup>57</sup>    | Case-control    | United States  | 133           | 142      | Patients with liver disease and controls who were total abstainers or who drank only moderate amounts of alcohol   | 24 (18)         | 17 (12)  | Cirrhosis  | NR                   |

DD, Dupuytren disease; NR, not reported.

\*Case-control studies were defined as studies including a group of patients suffering from liver disease, and a control group. Cross-sectional studies were defined as studies including one group, in which the presence of liver disease and Dupuytren disease was determined.

**Table 5. Characteristics of Articles Included in the Meta-Analysis on the Association between Dupuytren Disease and Epilepsy**

| Reference                                 | Design*         | Country        | Study Size |          | Study Sample  | No. with DD (%) |           | What Medication  |
|---|-----------------|----------------|------------|----------|---|-----------------|-----------|--|
|   |                 |                | Epilepsy   | Controls |   | Epilepsy        | Controls  |  |
| Arafa et al., 1992 <sup>23</sup>          | Case-control    | United Kingdom | 715        | 555      | Epileptic patients and nonepileptic patients from fracture clinic as controls                   | 183 (26)        | 89 (16)   | Phenytoin, phenobarbital, primidone, carbamazepine   |
| Geoghegan et al., 2004 <sup>84</sup>      | Case-control    | United Kingdom | 22         | 2441     | Epileptic patients and nonepileptic controls  | 10 (45)         | 811 (33)  | Phenytoin, barbiturates, carbamazepine, valproate  |
| Laplane and Carydakis, 1985 <sup>91</sup> | Case-control    | France         | 191        | 150      | Epileptic patients and nonepileptic neurologic patients who never used barbiturates as controls | 15 (8)          | 9 (6)     | Barbiturates, primidone, phenytoin, valproate, carbamazepine, ethosuximide, clonazepam, diazepam |
| Lucas et al., 2008 <sup>12</sup>          | Cross-sectional | France         | 16         | 2194     | Epileptic patients and nonepileptic controls  | 6 (38)          | 206 (9)   | NR   |
| Macaulay et al., 2012 <sup>60</sup> †     | Case-control    | United States  | 112        | 2700     | Epileptic patients and nonepileptic controls  | 79 (71)         | 1327 (49) | NR   |
| Seidler et al., 2001 <sup>32</sup> ‡      | Case-control    | Germany        | 6          | 622      | Epileptic patients and nonepileptic controls  | 2 (33)          | 283 (46)  | NR   |

DD, Dupuytren disease; NR, not reported.

\*Case-control studies were defined as studies including a group of patients suffering from epilepsy, and a control group. Cross-sectional studies were defined as studies including one group in which the presence of epilepsy and Dupuytren disease was determined.


†In these studies, the presence of epilepsy was determined in a group of Dupuytren patients and in controls.

that occur as a result of diabetes mellitus cause oxidative stress that produces advanced-glycated end-products.<sup>63,64</sup> Advanced-glycated end-products interact with advanced-glycated end-product receptors present on cell surfaces, which causes up-regulation of transforming growth factor (TGF)- $\beta$ .<sup>65</sup> TGF- $\beta$  plays a key role in the pathology of fibrotic diseases, and up-regulation has been associated with Dupuytren disease.<sup>66,67</sup> In addition, the up-regulation of TGF- $\beta$  also causes synthesis of type III collagen, the type of collagen that is predominantly found in Dupuytren disease tissue.<sup>68,69</sup> Moreover, collagen tends to stiffen by cross-linking because of nonenzymatic glycation.<sup>70</sup> Furthermore, biochemical studies have shown that diabetes mellitus metabolites stimulate the development of myofibroblasts,<sup>71</sup> the most important cell in Dupuytren disease nodules. Thus, it has been shown that biochemical consequences of diabetes mellitus play an important role in fibrotic diseases. Therefore, it is likely that the same pathogenic pathways underlie the association between Dupuytren disease and diabetes mellitus. In addition, it is possible that the peripheral vascular changes that can occur as a consequence of diabetes mellitus aggravate the oxidative stress. This has previously been suggested as a trigger for Dupuytren disease.<sup>72,73</sup> There was no statistically significant difference between the odds ratio of diabetes mellitus type 1 and type 2.


We further demonstrated an association between Dupuytren disease and liver disease, although the type of liver disease could not be addressed in the meta-analysis, because the data were not reported separately. Unfortunately, the effect of alcohol consumption in this association could not be determined either, because only one included article reported the amount of alcohol consumed in each group.<sup>4</sup> However, we were able to correct the analysis for differences in sex distribution. Multiple studies have shown that men consume more alcohol than women,<sup>74-77</sup> although this difference has become less pronounced in the past decade.<sup>78</sup> Therefore, sex can be considered as a proxy variable for alcohol consumption. This way, one could argue that our analyses were corrected for the indirect effects of alcohol consumption. Interestingly, animal studies indicate that the formation of advanced-glycated end-products also plays a role in alcoholic liver disease.<sup>79</sup> Furthermore, both diabetes mellitus and alcohol consumption are responsible for alterations in glucose homeostasis.<sup>80,81</sup>

Our results showed that Dupuytren disease and epilepsy are associated, but the suspected





**Fig. 2.** Forest plot showing the association between Dupuytren disease and diabetes mellitus as calculated from the different articles. The size of the *square* indicates the weight of the study. The horizontal lines represent the 95 percent confidence interval. Note that this figure shows crude odds ratios.




**Fig. 3.** Forest plot showing the association between Dupuytren disease and liver disease as calculated from the different articles. The size of the *square* indicates the weight of the study. Note that this figure shows crude odds ratios.

role of anticonvulsant medication could not be defined in this meta-analysis. However, one article that studied the association between Dupuytren disease and epilepsy reported data for each medication type separately.<sup>8</sup> In this article, an association between the two diseases was demonstrated, but no associations between specific anticonvulsants and Dupuytren disease were found. The

authors argue that the association between the two diseases might be caused by ascertainment bias.

Publication bias is always a concern in meta-analyses. However, we did not look for funnel plot asymmetry, as the number of included articles was small. This was especially the case in the meta-analysis of Dupuytren disease and liver disease,



**Fig. 4.** Forest plot showing the association between Dupuytren disease and epilepsy as calculated from the different articles. The size of the *square* indicates the weight of the study.

and epilepsy. The statistical tests would lack power to identify asymmetry. Moreover, commonly used tests such as the Begg test or the Egger test cannot be used, because the outcome in this study is dichotomous. There are alternatives for examining funnel plot asymmetry in these cases<sup>82</sup> that are available in software packages such as R. However, these methods cannot manage meta-analyses in which covariates are included.

Although we planned to correct the association between Dupuytren disease and liver disease for the amount of alcohol consumed, this was not possible, because those data were not reported in the included studies. In such cases, it is advised to contact the authors for additional information. However, the included articles were published more than 20 years ago (1956 to 1992), making it difficult to contact the authors. Therefore, we want to emphasize that the results of our meta-analyses do not present information about causality. Furthermore, there were two articles in the association between Dupuytren disease and liver disease with a confidence interval overlapping 1.0. This indicates that the association was not significant, whereas the other articles demonstrated a significant association. However, the intraclass correlation coefficient indicated that heterogeneity was very low. Although this may seem contradictory, the point estimates of these studies were above an odds ratio of 1.0. The low intraclass correlation coefficient value ensures that this overlap is not caused by heterogeneity, but rather by a lack of sample size within studies, leading to a wide confidence interval. The same was seen in the association between Dupuytren disease and diabetes mellitus.

A weakness of this study is that the quality of the articles was not determined using a quality assessment tool. We had several reasons for this. First, there is no single quality assessment tool available for observational studies.<sup>83,84</sup> Second,

and more importantly, there are multiple studies indicating that a quality score should not be used to weight, rank, or value the articles included in a meta-analysis.<sup>85–88</sup> Furthermore, the quality assessment score is often not related to effect size and heterogeneity.<sup>89</sup> The Cochrane Collaboration provides an alternative judgment system, evaluating risk of bias. However, this system is focused on randomized controlled trials and not on observational studies.

We noticed that the definition of Dupuytren disease varied widely across studies. For example, some authors did not report anything about the definition at all,<sup>8,32,59</sup> whereas others clearly stated the definition they used for Dupuytren disease.<sup>23,28,58</sup> (See **Table, Supplemental Digital Content 2**, in which details on diagnosis and definitions of Dupuytren disease and diabetes mellitus are reported, along with definitions of control groups and information on age as a potential confounder, <http://links.lww.com/PRS/C638>. See **Table, Supplemental Digital Content 3**, in which details on diagnosis and definitions of Dupuytren disease are reported, along with definitions of control groups and information on sex as a potential confounder, <http://links.lww.com/PRS/C639>. See **Table, Supplemental Digital Content 4**, in which details on diagnosis and definitions of Dupuytren disease are reported, along with definitions of control groups, <http://links.lww.com/PRS/C640>.) Some only took alterations in the fourth or fifth digit into account.<sup>33,54</sup> Furthermore, the populations from which the control subjects were selected were diverse. In some studies, the controls were randomly selected from the general population,<sup>32</sup> whereas in other studies the controls were patients from a specific hospital department.<sup>28</sup> Although this increases the variability between studies, it would lead to an underestimation of the association strength rather than an overestimation.

Because of the correction for potential confounders, the results of these meta-analyses provide a more reliable estimation of the association between Dupuytren disease and diabetes mellitus, liver disease, and epilepsy. Future studies should elucidate the causal pathways that underlie these associations. Until then, clinicians and researchers studying Dupuytren disease should be aware of these associations and correct for them in their study design or analyses.

**Dieuwke C. Broekstra, M.Sc.**

Department of Plastic Surgery BB81  
University of Groningen  
University Medical Center Groningen  
Hanzeplein 1  
9700 RB Groningen, The Netherlands  
d.c.broekstra@umcg.nl

### ACKNOWLEDGMENT

The authors would like to thank Aletta A. J. Buurma, M.D., Ph.D., for help with screening the articles and collecting data.

### REFERENCES

- Hindocha S, John S, Stanley JK, Watson SJ, Bayat A. The heritability of Dupuytren's disease: Familial aggregation and its clinical significance. *J Hand Surg Am.* 2006;31:204–210.
- Dolmans GH, Werker PM, Hennies HC, et al.; Dutch Dupuytren Study Group; German Dupuytren Study Group; LifeLines Cohort Study; BSSH-GODD Consortium. Wnt signaling and Dupuytren's disease. *N Engl J Med.* 2011;365:307–317.
- Dolmans GHCG, Wijmenga C, Ophoff R, Werker PMN. A clinical genetic study of familial Dupuytren's disease in the Netherlands. In: Eaton C, eds. *Dupuytren's Disease and Related Hyperproliferative Disorders.* Springer, Berlin, Heidelberg; 2012.
- Attali P, Ink O, Pelletier G, et al. Dupuytren's contracture, alcohol consumption, and chronic liver disease. *Arch Intern Med.* 1987;147:1065–1067.
- Mikkelsen OA. Dupuytren's disease: The influence of occupation and previous hand injuries. *Hand* 1978;10:1–8.
- Lanting R, van den Heuvel ER, Westerink B, Werker PM. Prevalence of Dupuytren disease in The Netherlands. *Plast Reconstr Surg.* 2013;132:394–403.
- Descatha A, Carton M, Mediouni Z, et al. Association among work exposure, alcohol intake, smoking and Dupuytren's disease in a large cohort study (GAZEL). *BMJ Open* 2014;4:e004214.
- Geoghegan JM, Forbes J, Clark DI, Smith C, Hubbard R. Dupuytren's disease risk factors. *J Hand Surg Br.* 2004;29:423–426.
- Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. *Nat Rev Rheumatol.* 2010;6:715–726.
- Reilly RM, Stern PJ, Goldfarb CA. A retrospective review of the management of Dupuytren's nodules. *J Hand Surg Am.* 2005;30:1014–1018.
- Becker K, Tinschert S, Lienert A, et al. The importance of genetic susceptibility in Dupuytren's disease. *Clin Genet.* 2015;87:483–487.
- Lucas G, Brichet A, Roquelaure Y, Leclerc A, Descatha A. Dupuytren's disease: Personal factors and occupational exposure. *Am J Ind Med.* 2008;51:9–15.
- Kovacs D, Demian L, Babes A. Prevalence and risk of Dupuytren disease in patients with diabetes versus non-diabetic patients. *Rom J Diabetes Nutr Metab Dis.* 2012;19:373–380.
- Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. *J Bone Joint Surg Br.* 1984;66:322–325.
- Machtley I. Dupuytren's disease and diabetes mellitus. *J Rheumatol.* 1997;24:2489–2490.
- Savaş S, Koroğlu BK, Koyuncuoğlu HR, Uzar E, Celik H, Tamer NM. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. *Diabetes Res Clin Pract.* 2007;77:77–83.
- Ravid M, Dinai Y, Sohar E. Dupuytren's disease in diabetes mellitus. *Acta Diabetol Lat.* 1977;14:170–174.
- Carson J, Clarke C. Dupuytren's contracture in pensioners at the Royal Hospital Chelsea. *J R Coll Physicians Lond.* 1993;27:25–27.
- Bridgman JF. Periarthritis of the shoulder and diabetes mellitus. *Ann Rheum Dis.* 1972;31:69–71.
- Mattson RH, Cramer JA, McCutchen CB. Barbiturate-related connective tissue disorders. *Arch Intern Med.* 1989;149:911–914.
- Fröscher W, Hoffmann F. Dupuytren's contracture and phenobarbital administration in epilepsy patients (in German). *Nervenarzt* 1983;54:413–419.
- Mattioli-Foggia C. Dupuytren's disease and epilepsy (in Italian). *Riv Neurobiol.* 1965;11:207–211.
- Arafa M, Noble J, Royle SG, Trail IA, Allen J. Dupuytren's and epilepsy revisited. *J Hand Surg Br.* 1992;17:221–224.
- Critchley EM, Vakil SD, Hayward HW, Owen VM. Dupuytren's disease in epilepsy: Result of prolonged administration of anticonvulsants. *J Neurol Neurosurg Psychiatry* 1976;39:498–503.
- Larkin ME, Barnie A, Braffett BH, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Musculoskeletal complications in type 1 diabetes. *Diabetes Care* 2014;37:1863–1869.
- Sturfelt G, Leden E, Nived O. Hand symptoms associated with diabetes mellitus: An investigation of 765 patients based on a questionnaire. *Acta Med Scand.* 1981;210:35–38.
- Ravindran Rajendran S, Bhansali A, Walia R, Dutta P, Bansal V, Shanmugasundar G. Prevalence and pattern of hand soft-tissue changes in type 2 diabetes mellitus. *Diabetes Metab.* 2011;37:312–317.
- Ardic F, Soyupek F, Kahraman Y, Yorgancioglu R. The musculoskeletal complications seen in type II diabetics: Predominance of hand involvement. *Clin Rheumatol.* 2003;22:229–233.
- Cagliero E, Apruzzese W, Perlmutter GS, Nathan DM. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. *Am J Med.* 2002;112:487–490.
- Eadington DW, Patrick AW, Frier BM. Association between connective tissue changes and smoking habit in type 2 diabetes and in non-diabetic humans. *Diabetes Res Clin Pract.* 1991;11:121–125.
- Pal B, Griffiths ID, Anderson J, Dick WC. Association of limited joint mobility with Dupuytren's contracture in diabetes mellitus. *J Rheumatol.* 1987;14:582–585.
- Seidler A, Stolte R, Nienhaus A, Windolf J, Elsner G. Occupational, consumption-related and disease-related risk factors for Dupuytren's contracture: Results of a case-control study. *Arbeitsmed Sozialmed Umweltmed.* 2001;36:218–229.

33. Spring M, Fleck H, Cohen BD. Dupuytren's contracture: Warning of diabetes? *N Y State J Med.* 1970;70:1037–1041.
34. Zerajic D, Finsen V. Dupuytren's disease in Bosnia and Herzegovina: An epidemiological study. *BMC Musculoskeletal Disord.* 2004;5:10.
35. Gordon S. Dupuytren's contracture: The significance of various factors in its etiology. *Ann Surg.* 1954;140:683–686.
36. Hnanicek J, Cimbuřova M, Putova I, et al. Lack of association of iron metabolism and Dupuytren's disease. *J Eur Acad Dermatol Venereol.* 2008;22:476–480.
37. Ladjimi A, Youssef S, Chamakhi S, et al. Rheumatologic manifestations in diabetes (in French). *Tunis Med.* 1985;63:213–219.
38. Larkin JG, Frier BM. Limited joint mobility and Dupuytren's contracture in diabetic, hypertensive, and normal populations. *Br Med J (Clin Res Ed.)* 1986;292:1494.
39. Quintana Guitian A. Various epidemiologic aspects of Dupuytren's disease (in French). *Ann Chir Main* 1988;7:256–262.
40. Rafter D, Kenny R, Gilmore M, Walsh CH. Dupuytren's contracture: A survey of a hospital population. *Ir Med J.* 1980;73:227–228.
41. Revach M, Cabilli C. Dupuytren's contracture and diabetes mellitus. *Isr J Med Sci.* 1972;8:774–775.
42. Tajika T, Kobayashi T, Kaneko T, et al. Epidemiological study for personal risk factors and quality of life related to Dupuytren's disease in a mountain village of Japan. *J Orthop Sci.* 2014;19:64–70.
43. Burke FD, Proud G, Lawson IJ, McGeoch KL, Miles JN. An assessment of the effects of exposure to vibration, smoking, alcohol and diabetes on the prevalence of Dupuytren's disease in 97,537 miners. *J Hand Surg Eur Vol.* 2007;32:400–406.
44. Gudmundsson KG, Arngrímsson R, Sigfússon N, Björnsson A, Jónsson T. Epidemiology of Dupuytren's disease: Clinical, serological, and social assessment. The Reykjavik Study. *J Clin Epidemiol.* 2000;53:291–296.
45. Heathcote JG, Cohen H, Noble J. Dupuytren's disease and diabetes mellitus. *Lancet* 1981;1:1420.
46. Ramchurn N, Mashamba C, Leitch E, et al. Upper limb musculoskeletal abnormalities and poor metabolic control in diabetes. *Eur J Intern Med.* 2009;20:718–721.
47. Houghton S, Holdstock G, Cockerell R, Wright R. Dupuytren's contracture, chronic liver disease and IgA immune complexes. *Liver* 1983;3:220–224.
48. Ouédraogo DD, Tiéno H, Ouédraogo LT, et al. Rheumatologic manifestations in black African patients affected by diabetes mellitus. *Med Mal Metab.* 2009;3:520–523.
49. Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P. Direct and indirect costs associated with Dupuytren's contracture. *J Med Econ.* 2012;15:664–671.
50. Aydeniz A, Gursoy S, Guney E. Which musculoskeletal complications are most frequently seen in type 2 diabetes mellitus? *J Int Med Res.* 2008;36:505–511.
51. Cederlund RI, Thomsen N, Thrainsdóttir S, Eriksson KF, Sundkvist G, Dahlin LB. Hand disorders, hand function, and activities of daily living in elderly men with type 2 diabetes. *J Diabetes Complications* 2009;23:32–39.
52. Chammas M, Bousquet P, Renard E, Poirier JL, Jaffiol C, Allieu Y. Dupuytren's disease, carpal tunnel syndrome, trigger finger, and diabetes mellitus. *J Hand Surg Am.* 1995;20:109–114.
53. Renard E, Jacques D, Chammas M, et al. Increased prevalence of soft tissue hand lesions in type 1 and type 2 diabetes mellitus: Various entities and associated significance. *Diabetes Metab.* 1994;20:513–521.
54. Bergaoui N, Dibej K, el May M. Association of cheiroarthropathy and Dupuytren's disease in diabetes mellitus (in French). *Rev Rhum Mal Osteoartic.* 1991;58:179–181.
55. Chen LH, Li CY, Kuo LC, et al. Risk of hand syndromes in patients with diabetes mellitus: A population-based cohort study in Taiwan. *Medicine (Baltimore)* 2015;94:e1575.
56. Günther O, Miosga R. Dupuytren's contracture as a late complication of diabetes (in German). *Z Gesamte Inn Med.* 1972;27:777–782.
57. Su CK, Patek AJ Jr. Dupuytren's contracture: Its association with alcoholism and cirrhosis. *Arch Intern Med.* 1970;126:278–281.
58. Davidson CS, Summerskill WH, Wolfe SJ. Thickening and contraction of the palmar fascia (Dupuytren's contracture) associated with alcoholism and hepatic cirrhosis. *N Engl J Med.* 1956;255:559–563.
59. Bertrand J, Thomas J, Metman EH. Dupuytren's contracture and palmar erythema in alcoholic cirrhosis (in French). *Sem Hop.* 1977;53:407–412.
60. Noble J, Arafa M, Royle SG, McGeorge G, Crank S. The association between alcohol, hepatic pathology and Dupuytren's disease. *J Hand Surg Br.* 1992;17:71–74.
61. Laplane D, Carydakis C. Side effects of antiepileptic therapy: Study of 197 cases (in French). *Rev Neurol (Paris)* 1985;141:447–455.
62. Han J, Tan C, Wang Y, Yang S, Tan D. Betanin reduces the accumulation and cross-links of collagen in high-fructose-fed rat heart through inhibiting non-enzymatic glycation. *Chem Biol Interact.* 2015;227:37–44.
63. Bodiga VL, Eda SR, Bodiga S. Advanced glycation end products: Role in pathology of diabetic cardiomyopathy. *Heart Fail Rev.* 2014;19:49–63.
64. Schalkwijk CG, Baidoshvili A, Stehouwer CD, van Hinsbergh VW, Niessen HW. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: Generation and characterisation of a monoclonal anti-CML antibody. *Biochim Biophys Acta* 2004;1636:82–89.
65. Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. *Nephrol Dial Transplant.* 1996;11(Suppl 5):62–65.
66. Zhang AY, Fong KD, Pham H, Nacamuli RP, Longaker MT, Chang J. Gene expression analysis of Dupuytren's disease: The role of TGF-beta2. *J Hand Surg Eur Vol.* 2008;33:783–790.
67. Bayat A, Stanley JK, Watson JS, Ferguson MW, Ollier WE. Genetic susceptibility to Dupuytren's disease: Transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease. *Br J Plast Surg.* 2003;56:328–333.
68. Satish L, Gallo PH, Baratz ME, Johnson S, Kathju S. Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts. *BMC Musculoskeletal Disord.* 2011;12:113.
69. Brickley-Parsons D, Glimcher MJ, Smith RJ, Albin R, Adams JP. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. *J Bone Joint Surg Am.* 1981;63:787–797.
70. Vicens-Zygmunt V, Estany S, Colom A, et al. Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices. *Respir Res.* 2015;16:82.
71. Yuen A, Laschinger C, Talior I, et al. Methylglyoxal-modified collagen promotes myofibroblast differentiation. *Matrix Biol.* 2010;29:537–548.
72. Hueston JT, Murrell GA. Cell-controlling factors in Dupuytren's contracture. *Ann Chir Main Memb Super.* 1990;9:135–137.

73. Murrell GA, Francis MJ, Bromley L. Free radicals and Dupuytren's contracture. *Br Med J (Clin Res Ed.)* 1987;295:1373–1375.
74. Mäkelä P, Gmel G, Grittner U, et al. Drinking patterns and their gender differences in Europe. *Alcohol Alcohol Suppl.* 2006;41:i8–i18.
75. Nazareth I, Walker C, Ridolfi A, et al. Heavy episodic drinking in Europe: A cross section study in primary care in six European countries. *Alcohol Alcohol.* 2011;46:600–606.
76. Wilsnack RW, Vogeltanz ND, Wilsnack SC, et al. Gender differences in alcohol consumption and adverse drinking consequences: Cross-cultural patterns. *Addiction* 2000;95:251–265.
77. Wilsnack RW, Wilsnack SC, Kristjanson AF, Vogeltanz-Holm ND, Gmel G. Gender and alcohol consumption: Patterns from the multinational GENACIS project. *Addiction* 2009;104:1487–1500.
78. White A, Castle IJ, Chen CM, Shirley M, Roach D, Hingson R. Converging patterns of alcohol use and related outcomes among females and males in the United States, 2002 to 2012. *Alcohol Clin Exp Res.* 2015;39:1712–1726.
79. Hayashi N, George J, Takeuchi M, et al. Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease. *PLoS One* 2013;8:e70034.
80. Huang Z, Sjöholm A. Ethanol acutely stimulates islet blood flow, amplifies insulin secretion, and induces hypoglycemia via nitric oxide and vagally mediated mechanisms. *Endocrinology* 2008;149:232–236.
81. Rasmussen BM, Orskov L, Schmitz O, Hermansen K. Alcohol and glucose counterregulation during acute insulin-induced hypoglycemia in type 2 diabetic subjects. *Metabolism* 2001;50:451–457.
82. Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses with binary outcomes. *Stat Med.* 2008;27:746–763.
83. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: A systematic review and annotated bibliography. *Int J Epidemiol.* 2007;36:666–676.
84. Shamliyan T, Kane RL, Dickinson S. A systematic review of tools used to assess the quality of observational studies that examine incidence or prevalence and risk factors for diseases. *J Clin Epidemiol.* 2010;63:1061–1070.
85. Herbison P, Hay-Smith J, Gillespie WJ. Adjustment of meta-analyses on the basis of quality scores should be abandoned. *J Clin Epidemiol.* 2006;59:1249–1256.
86. Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. *BMC Med Res Methodol.* 2005;5:19.
87. Greenland S, O'Rourke K. On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. *Biostatistics* 2001;2:463–471.
88. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. *JAMA* 1999;282:1054–1060.
89. Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC. An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. *Control Clin Trials* 1990;11:339–352.